IXICO chief executive Derek Hill caught up with Proactive to discuss the company’s full year results and new partnerships.
Hill tells Proactive: We’re very focused on the brain. Neurodegenerative diseases have been our longer term focus – the perhaps best known one of those – Alzheimer’s Disease which is the main cause of dementia.”
”Traditionally IXICO has, for the last 12 years, been working with pharmaceutical companies supporting them in developing drugs, particularly for neurodegenerative diseases … but recently we’ve also got some of our technology crossing over from the world of developing drugs into being used alongside drugs in the clinics”.
”We’re using technology that we have for many years been applying to support pharmaceutical companies developing drugs. We’re now using that to help make those drugs safer when used with patients in the clinic once they’re marketed”, Hill added.
Hill went on to say: ”We are involved in several European projects which are collaborations with the pharmaceutical industry but also with major academic centres across Europe”’.
Story by ProactiveInvestors